Wednesday, December 17, 2025
VIRTUAL EVENT
Time for a Radical Reset: A CEO and Investor Make the Case for Leaner Biotech
U.S. biotech is facing a tougher capital environment, rising development costs, and growing pressure to show real discipline.
With investors and pharma increasingly looking to China for assets and opportunities, some leaders argue the industry needs a reset: leaner teams, sharper prioritization, and faster decision cycles.
Ken Song, the CEO of Candid Therapeutics, and investor Leon Chen of The Column Group share their own views on where the worst inefficiency lies and how CEOs, boards, and investors can build smarter companies.
Join us for a lively discussion and practical takeaways.
